CDK1 and nasopharyngeal carcinoma: Taken together, these data demonstrate that roniciclib has an antiproliferative effect on NPC cells and acts to prevent cell cycle progression at G1/S phase via Rb, RNA polymerase II, and NPM dephosphorylation and to prevent cell division at G2/M via CDK1 repression, eventually leading to cell death.